Cambrooke Therapeutics
Cambrooke Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Cambrooke Therapeutics.
Cambrooke Therapeutics is a company.
Key people at Cambrooke Therapeutics.
Cambrooke Therapeutics, now operating as Ajinomoto Cambrooke, Inc. since 2019, is a Massachusetts-based therapeutic nutrition company founded in 2000 that develops and commercializes medical nutrition products for patients with serious unmet needs, primarily in inborn errors of metabolism (IEM) like PKU, tyrosinemia, and homocystinuria, as well as intractable epilepsy, disease-related malnutrition, oncology, cystic fibrosis, and severe protein allergy.[1][2][3][4][5] The company serves patients, physicians, and researchers worldwide by creating innovative formulas such as Glytactin (the first natural whole protein medical food for PKU launched in 2010), KetoVie (a plant-based ketogenic formula for epilepsy), and Essential Care Jr. (a corn syrup-solid-free amino acid formula for allergies and GI disorders), addressing dietary restrictions that limit quality of life.[1][3][4] With global expansion through acquisitions like Nualtra in Ireland and partnerships (e.g., University of Wisconsin for Glytactin with GMP), it generates around $18 million in revenue and employs 83 people, demonstrating steady growth in specialized medical nutrition.[2][3][5]
Cambrooke began in 2000 as a passion project focused on low-protein foods to ease the burden on families managing PKU, starting with innovations like bread without flour, cheese without milk, and egg alternatives, which expanded to ready-to-drink amino acid formulas and meat substitutes for various metabolic disorders.[3] The company evolved into Cambrooke Therapeutics to reflect its broader therapeutic nutrition portfolio, pioneering products like Glytactin BETTERMILK in 2010—the first natural whole protein formula for PKU—followed by expansions into epilepsy (KetoVie) and allergies.[1][3] A pivotal acquisition by Ajinomoto Group led to the 2019 rebranding as Ajinomoto Cambrooke, Inc., enhancing global reach with "just add water" scalability and further growth via the Nualtra acquisition for malnutrition products in the UK and Ireland.[2][3][5] Early traction came from collaborations with global physicians and researchers, humanizing its mission of "living without limits" for patients facing chronic conditions.[1][3][4]
Cambrooke rides the wave of precision medical nutrition, where advances in metabolic science and personalized medicine demand tailored formulas for rare diseases, amplified by growing awareness of IEM, epilepsy, and malnutrition amid aging populations and chronic disease prevalence.[1][4][5] Timing aligns with regulatory shifts favoring food-as-medicine (e.g., FMSPs reimbursable via NHS/HSE) and plant-based innovations, positioning it against market forces like supply chain demands for allergen-free, sustainable nutrition.[3][5] As part of Ajinomoto Group, it influences the ecosystem by setting standards for GMP-derived proteins and ketogenic therapies, fostering collaborations that bridge research to commercialization and expanding access in underserved global markets like Europe and Australia.[2][3]
Cambrooke is poised for accelerated global expansion through Ajinomoto-backed acquisitions and R&D, potentially deepening portfolios in oncology, cystic fibrosis, and protein allergies while scaling Nualtra's malnutrition solutions.[5] Trends like AI-driven formula personalization, rising demand for kosher/plant-based options, and malnutrition focus in chronic care will shape its path, evolving its influence from PKU pioneer to comprehensive therapeutic nutrition leader. This builds on its legacy, ensuring patients continue "living without limits" amid a $18M revenue base targeting broader unmet needs.[2][3][4]
Key people at Cambrooke Therapeutics.
